Specifically, patients that achieved CR were found to have significantly higher tumor inflammation signature, FOXP3, CD8 ̧inflammatory chemokine and PD-1 expression scores at baseline as compared to non-responders. The gene discussed is PDCD1; the disease is neoplasm.